Understanding Heterogeneity in Patients' Conceptualisation of Treatment for Rheumatoid Arthritis: A Cluster Analysis
- PMID: 37666546
- PMCID: PMC10481841
- DOI: 10.1136/bmjopen-2022-070848
Understanding Heterogeneity in Patients' Conceptualisation of Treatment for Rheumatoid Arthritis: A Cluster Analysis
Abstract
Objective: Uptake of treat-to-target (TTT) strategies for rheumatoid arthritis (RA) management is low. Our objective was to understand the heterogeneity in patients' conceptualisation of RA treatment to inform interventions improving TTT uptake.
Design: Eligible participants recruited from an online research registry rated 56 items (on 5-point scales) reflecting concepts raised from patient interviews. Using items describing adhering to physician recommendations to create a binary criterion variable for medication adherence, we conducted a principal components analysis on the remaining items using Varimax rotation, describing how these factors predict adherence over and above demographic characteristics. We further use optimal sets in regression to identify the individual concepts that are most predictive of medication adherence.
Results: We found significant heterogeneity in patients' conceptualisation of RA treatment among 621 persons with RA. A scree plot revealed a four-factor solution explained 38.4% of the variance. The four factors expected to facilitate TTT uptake were (% variance explained): (1) Access to high quality care and support (11.3%); (2) low decisional conflict related to changing disease-modifying antirheumatic drugs (DMARDs) (10.1%); (3) endorsement of a favourable DMARD risk/benefit ratio (9.9%); and (4) confidence that testing reflects disease activity (7.2%). These factors account for 13.8% of the variance in full medication adherence, fully explaining the only significant demographic predictor, age of the patient. The individual items most predictive of poor adherence centre on the lack of effective patient-physician communication, specifically insufficient access to information from rheumatologists, along with the need to seek information elsewhere.
Conclusion: Patients' conceptualisation of RA treatment varies; however, almost all patients have difficulty escalating DMARDs, even with access to quality information and an understanding of the benefits of TTT. Tailored interventions are needed to address patient hesitancy to escalate DMARDs.
Keywords: QUALITATIVE RESEARCH; RHEUMATOLOGY; Rheumatology.
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: JRC: received research funding from AbbVie, Amgen, Bristol Myers Squibb, CorEvitas, Janssen, Lilly, Novartis, Myriad, Pfizer, Sanofi, Setpoint, Schipher, UCB and served as a consultant for AbbVie, Amgen, Bristol Myers Squibb, Corevitas, Janssen, Lilly, Novartis, Myriad, Pfizer, Sanofi, Setpoint, Schipher, UCB. LH: employee and shareholder of CorEvitas LLC; a consultant to AbbVie, Bristol Myers Squibb and Roche; speakers bureau for Bristol Myers Squibb.
Similar articles
-
Healthcare professionals' perceptions on barriers and facilitators to DMARD use in rheumatoid arthritis.BMC Health Serv Res. 2022 Jan 13;22(1):62. doi: 10.1186/s12913-021-07459-0. BMC Health Serv Res. 2022. PMID: 35022034 Free PMC article.
-
Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.Clin Ther. 2016 Mar;38(3):646-54. doi: 10.1016/j.clinthera.2016.01.022. Epub 2016 Feb 18. Clin Ther. 2016. PMID: 26899313
-
"It's so hard taking pills when you don't know what they're for": a qualitative study of patients' medicine taking behaviours and conceptualisation of medicines in the context of rheumatoid arthritis.BMC Health Serv Res. 2017 Apr 26;17(1):303. doi: 10.1186/s12913-017-2246-8. BMC Health Serv Res. 2017. PMID: 28441949 Free PMC article.
-
Management of rheumatoid arthritis: 2019 updated consensus recommendations from the Hong Kong Society of Rheumatology.Clin Rheumatol. 2019 Dec;38(12):3331-3350. doi: 10.1007/s10067-019-04761-5. Epub 2019 Sep 4. Clin Rheumatol. 2019. PMID: 31485846 Review.
-
Patients' Attitudes and Experiences of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis and Spondyloarthritis: A Qualitative Synthesis.Arthritis Care Res (Hoboken). 2018 Apr;70(4):525-532. doi: 10.1002/acr.23329. Epub 2018 Mar 24. Arthritis Care Res (Hoboken). 2018. PMID: 28732151 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical